A multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a new HIV therapy called lenacapavir in a population of patients in Uganda.
The study, published Jan. 30 in the Journal of Antimicrobial Chemotherapy, adds to growing evidence that lenacapavir may be a powerful new tool in the global anti-HIV drug arsenal. Approximately, 1.5 million people are living with HIV in Uganda.
“Our data shows that only 1.6% of the individuals studied are living with HIV strains that have any known lenacapavir-associated resistance mutations,” said senior author Dr. Guinevere Lee, assistant professor of virology in medicine at Weill Cornell Medicine. “That’s important because it shows lenacapavir is likely to be effective against strains of HIV circulating in East Africa.”
Dr. Guinevere Lee
